Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 15,175 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of December 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亞州諾瓦託,2024年12月20日(GLOBE NEWSWIRE)——專注於開發和商業化罕見和超罕見疾病新療法的生物製藥公司Ultragenyx Pharmaceutical Inc.(納斯達克股票代碼:RARE)今天報告說,向該公司15名新聘的非執行官員發放了15,175股公司普通股的限制性股票。這些獎勵已獲得公司董事會薪酬委員會的批准,並根據Ultragenyx就業激勵計劃發放,發放日期爲2024年12月16日,作爲激勵新員工根據納斯達克上市規則5635(c)(4)進入Ultragenyx工作的激勵材料。
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
限制性股票單位的歸屬期爲四年,25%的標的股票在授予日的每個週年紀念日歸屬,前提是員工自該歸屬之日起一直受僱於公司。
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
Ultragenyx 製藥公司簡介
Ultragenyx是一家生物製藥公司,致力於爲患者提供用於治療嚴重的罕見和超罕見遺傳病的新產品。該公司已經建立了多元化的經批准的療法和候選產品組合,旨在解決未得到滿足的醫療需求和明確的治療生物學特徵的疾病,對於這些疾病,通常沒有經批准的治療基礎疾病的療法。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
該公司由一支在罕見病療法開發和商業化方面經驗豐富的管理團隊領導。Ultragenyx的戰略以具有時間和成本效益的藥物開發爲前提,目標是緊急爲患者提供安全有效的療法。
For more information on Ultragenyx, please visit the company's website at: .
有關Ultragenyx的更多信息,請訪問該公司的網站:。
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
聯繫 Ultragenyx
投資者與媒體
約書亞·希加
(415) 475-6370